Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 2, 2026

Tech stocks today: Nvidia invests $4B in photonics makers, Apple announces low-cost iPhone, OpenAI strikes deal with Pentagon

View original at finance.yahoo.com
Tech stocks today: Nvidia invests $4B in photonics makers, Apple announces low-cost iPhone, OpenAI strikes deal with Pentagon Artificial intelligence leader Nvidia (NVDA) announced two new $2 billion investments into Coherent (COHR) and Lumentum (LITE), whose stocks jumped on Monday, as the AI giant looks to scale up i…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Latest iPad Airs are up to 30% faster than iPad Air with M3 processor and 2.3x faster than model with M1 chip

    80% confidence
  • Capital expenditures would increase from $15.4 billion in 2025 to at least $30 billion in 2026

    80% confidence
  • Our agreement has more guardrails than any previous agreement for classified AI deployments, including Anthropic's

    80% confidence
  • What we are witnessing is not a temporary squeeze, but a tsunami-like shock originating in the memory supply chain, with ripple effects spreading across the entire consumer electronics industry

    80% confidence
  • Data Center revenue for Q4 was record $62.3 billion, up 75% from a year ago and up 22% sequentially, driven by major platform shifts – accelerated computing and AI

    80% confidence
  • The global smartphone market, particularly Android manufacturers, faces a significant threat

    80% confidence
  • This is a simple, common-sense request that will prevent Anthropic from jeopardizing critical military operations and potentially putting our warfighters at risk

    80% confidence
  • Computing has fundamentally changed. In the age of AI, software runs on intelligence with tokens generated in real time by AI factories for every interaction and every context

    80% confidence
  • The contract language received overnight from the Department of War made virtually no progress on preventing Claude's use for mass surveillance of Americans or in fully autonomous weapons

    80% confidence
  • We retain full discretion over our safety stack, we deploy via cloud, cleared OpenAI personnel are in the loop, and we have strong contractual protections

    80% confidence
  • We cannot in good conscience accede to their request

    80% confidence
  • We don't need it, we don't want it, and will not do business with them again

    80% confidence
  • The Department of War has no interest in using AI to conduct mass surveillance of Americans (which is illegal) nor do we want to use AI to develop autonomous weapons that operate without human involvement

    80% confidence
  • I am confident in their cash flow growing

    80% confidence
  • The partnership remains strong and central between Microsoft and OpenAI

    80% confidence
  • OpenAI shares Anthropic's red lines on mass surveillance and autonomous weapons

    80% confidence
  • Anthropic would rather cut ties with government than cross two red lines: using models for mass surveillance of US citizens and using them to develop fully autonomous weapons

    80% confidence
  • For Q4, hyperscaler revenue increased and remained our largest customer category at slightly over 50% of Data Center revenue, while growth was led by the rest of our Data Center customers as revenue diversified

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com